Comments
Shares of Cadila Healthcare soared 9 per cent today after the drugmaker announced that Zydus Cadila has received final approval from the USFDA to market candesartan cilexetil tablets used for the treatment of hypertension.
The scrip rose 8.95 per cent to an intra-day high of Rs 503.90 on the BSE. It had opened at Rs 465.85. A similar movement was witnessed on the NSE where the stock moved higher by 8.93 per cent to Rs 504 during intra-day trade.
Cadila Healthcare is a part of Zydus Cadila.
In a regulatory filing to exchanges, Cadila Healthcare today said Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market candesartan cilexetil tablets in strengths of 4 mg, 8 mg, 16 mg and 32 mg.
The company will manufacture the drug at its formulation manufacturing facility in Moraiya in Ahmedabad. It has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it had commenced filings in 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.